DCF Psychotropic Medication Advisory Committee Monthly Meeting Notes

June 3, 2011 1:00PM Riverview Hospital for Children and Youth Middletown, CT.

PRESENT: David Aresco, Pharmacist; Wagar Azeem, M.D.; Patricia Cables, APRN; Debra Brown, M.D.; Carlos Gonzalez, M.D.; Jason Gott, DSS Pharmacist; Jacqueline Harris, M.D.; Irvin Jennings. M.D.; Monica Jensen, RN; Aurele Kamm, APRN; Brian Keyes, M.D.; Margaret Rudin, PhD APRN; Lesley Siegel, M.D.; Amy Veivia, Pharmacist.

- 1. Call to order: Dr. Siegel called the meeting to order at 1:10 pm.
- 2. Next Meeting: The next meeting will take place on Friday September 9th at 1:00.
- 3. Minutes: An updated version of the May 2011 meeting minutes was distributed and corrections noted.
- 4. Announcements: None.
- 5. DCF PMAC Bylaws review, discuss, propose and approve changes: The bylaws were distributed and discussed at length. The following issues/changes were discussed/recommended.
 - Use of the term "off label use". Change the word "often" to "frequently",
 - Change the word "burden" to "responsibility".
 - Change all "drug(s)" to "psychotropic medication(s)".
 Combine 1st and 2nd sentences.

 - □ Re-write entire **Purpose** section.
 - Under composition regarding parent advocate: change to "parent advocates are encouraged to participate".
 - Delete the sentence defining a quorum.
 - Delete item 8 under organization.
 - Change Duties to Responsibilities.
 - Under Responsibilities:
 - 1. #3: change "policies and procedures" to "recommendations".
 - 2. #4: change "in the agency" to "served by DCF".
 - 3. #7: change to "To create and maintain an approved list of safe and effective psychotropic medications for DCF involved children".
 - 4. #8: change "event" to "reaction".
 - 5. #9: Delete "These records may also be available electronically".

The PMAC voted to approve all recommendations.

- 6. Overview of Drug Information Inquiries(DII) received Apr-May 2011: The format regarding how this information should be presented was discussed. Amy Veivia reported that there were a total of 13 DII in April 2011 and 3 in May 2011. Each question was reviewed and discussed by the committee. Several issues were identified and will be investigated by the pharmacist consultants and reported back at the next meeting.
 - □ How do the safety profiles of Intuniv and Kapvay compare?
 - What may be the rationale for polypharmacy with antipsychotic medications?
 - Melatonin use.
 - 1. Look into European literature for relevant information on safety and effectiveness.
 - 2. Noted it is in use at DCF facilities: review current position statement(s) on use.
 - Determine the per-cent of children in the US taking herbal or OTC medications.
 - □ The Committee recommended and approved having <u>Overview of Drug</u> Information Inquiries as a standing agenda item.
- 7. Adjournment: The meeting was adjourned at 230pm.

Respectfully Submitted:

David S. Aresco